To evaluate the effectiveness of immunomodulatory mycophenolate mofetil in the treatment of scleritis. A retrospective non comparative review of seven cases of scleritis managed with mycophenolate mofetil at a tertiary eye hospital. The following information was extracted from the patients folders; socio-demographics, causes, type of scleritis, duration of scleritis, previous treatment on before commencement of mycophenolate mofetil (MMF), any systemic association, visual acuity (VA) at presentation and at the last hospital visit, laterality of the scleritis and the side effects experienced during the use of mycophenolate mofetil.Two patients with anterior nodular and four patients with diffuse anterior scleritis were identified. The mean follow up was 6 months. Six patients had the same pre-treatment VA and one patient had improved VA. No patient reported any side effect. All the inflammations were controlled in all the patients and no case of relapsed during the usage of MMF was reported. And no patient needed any additional immmunosupressive agents.Mycophenolate mofetil appears to be an effective drug in the management of anterior scleritis. The absence of side effects following its use is remarkable. It holds promise to reducing the blinding complication of scleritis. A further study with large sample size may be required to confirm our findings.
INTRODUCTION
Ocular inflammation is a common cause of ocular morbidity worldwide. 1, 2 Scleritis is an inflammation of sclera the tissue and usually associated with pain.
Scleritis is characterized by cellular infiltration and sclera oedema. Improper management of scleritis may result in visual impairment/ blindness. Scleritis affects women more often than men, with a peak incidence in the fifth decade 3 , it frequently starts in one eye and becomes bilateral in more than half of the cases. 3 Bilaterality is more commonly encountered in scleritis associated with systemic rheumatic disorders. The causes of scleritis include; idiopathic, infectious, collagen vascular disorders, drugs and surgery induced scleritis which was first described by Arensten et al. 4 MMF is an immunosuppressive agent, an ester morpholinoethyl of mycophenolic acid, with effective mode of action, by preventing the replication of T-and B-lymphocytes by inhibiting the de novo pathway of purine synthesis. 5 Since introduction of MMF in early 70's it has been used as immunomodulatory agents in prevention of acute renal grafting rejection 6 and treatment of many autoimmune systemic disorders. [7] [8] [9] [10] [11] Recently its use in the treatment of scleritis has been reported. [12] [13] [14] [15] [16] [17] However no such report has been reported in India population hence the purpose of this study is to describe our experience with the use of MMF in the treatment of patients with scleritis. and erythrocyte sedimentation rate (ESR) tests.
MATERIALS AND METHODS

This
Each patient was given questionnaire (Table 1) home to fill about the possible side effect she/he In a patient with bilateral scleritis visual acuity in the better eye was considered for interpreting result.
Simple frequency analysis was done.
Ethical clearance for the study was obtained from ethical and researcher committee of Sankara Nethralaya hospital Chennai, India.
RESULTS
Of the seven patients 2 were males and 5 were females (71.4%) with mean age of 46.9years (range 23-61years). Table 2 showed patients demographics.
Only one of the cases was a bachelor undergraduate. 15, 16 . MMF has been reported to be effective in the treatment of ocular inflammatory disease. 12, 16, [19] [20] [21] [22] All the case series responded well to MMF therapy with dose of 2 g daily for 2 weeks and thereafter 1g for 2 weeks this was similar to previous reported 23 .
But was different from Nida et al 12 who have to use 3 g of MMF to get maximal effect in their 4 patients.
The reason might be because of less severity of scleritis in our patients.
The studied case series did not report any side effect (both ocular and systemic) compared to other studies 12, 13, 22 . The reason may be because of short duration of our follow-up, possible genetic makeup in our patients and patient afraid of not receiving co-operation and attention of the eye care team if they report side effect. However this bias may be eliminated by prospective study at this centre.
Our study is limited because of retrospective nature of the study, small numbers of the patients and short duration of follow up.
